Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent
increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent. CJC1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility. The marked enhancement of through GH levels by continuous GHRH stimulation implicates the importance of this effect on increasing IGF-I. Long-acting GHRH preparations may have clinical utility in patients with intact pituitary GH secretory capability.
Reference:
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799- 805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.
 
National Institute of Health Research Link:
https://pubmed.ncbi.nlm.nih.gov/15817669/